Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.

Conference Proceedings

Laura Spring, Shom Goel, Sara Sutherland, Jeffrey G Supko, Dejan Juric, Steven J Isakoff, Erica L Mayer, Beverly Moy, Sara M Tolaney, Aditya Bardia

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2019